216 related articles for article (PubMed ID: 28978671)
21. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.
Zhu N; Chen M; Eng R; DeJong J; Sinha AU; Rahnamay NF; Koche R; Al-Shahrour F; Minehart JC; Chen CW; Deshpande AJ; Xu H; Chu SH; Ebert BL; Roeder RG; Armstrong SA
J Clin Invest; 2016 Mar; 126(3):997-1011. PubMed ID: 26878175
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.
Sadras T; Perugini M; Kok CH; Iarossi DG; Heatley SL; Brumatti G; Samuel MS; To LB; Lewis ID; Lopez AF; Ekert PG; Ramshaw HS; D'Andrea RJ
J Leukoc Biol; 2014 Jul; 96(1):83-91. PubMed ID: 24598054
[TBL] [Abstract][Full Text] [Related]
23. JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling.
Zhang Y; Xia F; Liu X; Yu Z; Xie L; Liu L; Chen C; Jiang H; Hao X; He X; Zhang F; Gu H; Zhu J; Bai H; Zhang CC; Chen GQ; Zheng J
J Clin Invest; 2018 May; 128(5):1737-1751. PubMed ID: 29584620
[TBL] [Abstract][Full Text] [Related]
24. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
[TBL] [Abstract][Full Text] [Related]
25. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.
Park SM; Cho H; Thornton AM; Barlowe TS; Chou T; Chhangawala S; Fairchild L; Taggart J; Chow A; Schurer A; Gruet A; Witkin MD; Kim JH; Shevach EM; Krivtsov A; Armstrong SA; Leslie C; Kharas MG
Cell Stem Cell; 2019 Jan; 24(1):153-165.e7. PubMed ID: 30472158
[TBL] [Abstract][Full Text] [Related]
26. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia.
Chu Y; Chen Y; Li M; Shi D; Wang B; Lian Y; Cheng X; Wang X; Xu M; Cheng T; Shi J; Yuan W
Cancer Sci; 2019 Jul; 110(7):2200-2210. PubMed ID: 31050834
[TBL] [Abstract][Full Text] [Related]
27. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
[TBL] [Abstract][Full Text] [Related]
28. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
[TBL] [Abstract][Full Text] [Related]
29. Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9.
Zhang LS; Kang X; Lu J; Zhang Y; Wu X; Wu G; Zheng J; Tuladhar R; Shi H; Wang Q; Morlock L; Yao H; Huang LJ; Maire P; Kim J; Williams N; Xu J; Chen C; Zhang CC; Lum L
EBioMedicine; 2019 Jan; 39():145-158. PubMed ID: 30528456
[TBL] [Abstract][Full Text] [Related]
30. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
31. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.
Ysebaert L; Chicanne G; Demur C; De Toni F; Prade-Houdellier N; Ruidavets JB; Mansat-De Mas V; Rigal-Huguet F; Laurent G; Payrastre B; Manenti S; Racaud-Sultan C
Leukemia; 2006 Jul; 20(7):1211-6. PubMed ID: 16688229
[TBL] [Abstract][Full Text] [Related]
32. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia.
Liu B; Ma H; Liu Q; Xiao Y; Pan S; Zhou H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):200. PubMed ID: 31097000
[TBL] [Abstract][Full Text] [Related]
33. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
[TBL] [Abstract][Full Text] [Related]
34. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.
Feder K; Edmaier-Schröger K; Rawat VPS; Kirsten N; Metzeler K; Kraus JM; Döhner K; Döhner H; Kestler HA; Feuring-Buske M; Buske C
Leukemia; 2020 Apr; 34(4):1027-1037. PubMed ID: 31758089
[TBL] [Abstract][Full Text] [Related]
35. Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.
Olme CH; Brown N; Finnon R; Bouffler SD; Badie C
Mutat Res; 2013 Aug; 756(1-2):119-26. PubMed ID: 23665297
[TBL] [Abstract][Full Text] [Related]
36. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
38. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
[TBL] [Abstract][Full Text] [Related]
39. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
[TBL] [Abstract][Full Text] [Related]
40. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
